ストックスクリーナーアプリを入手
5.165
2.91%
-0.155
前日終値:
$5.32
開ける：
$5.23
24時間の取引高:
4,312
Relative Volume:
0.00
時価総額：
$7.55M
収益：
-
当期純損益:
$-16.49M
株価収益率:
-0.1743
EPS:
-29.6295
ネットキャッシュフロー:
$-15.24M
1週間 パフォーマンス:
+1.87%
1か月 パフォーマンス:
+12.04%
6か月 パフォーマンス:
-11.25%
1年 パフォーマンス:
-52.57%
1日の値動き範囲:
$5.165
$5.23
1週間の範囲:
$4.37
$5.45
52週間の値動き範囲:
$1.90
$11.16
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
名前
Cns Pharmaceuticals Inc
セクター
電話
1-800-946-9185
住所
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
5.165 | 7.55M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-12-28 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 開始されました | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
CNS Pharmaceuticals(CNSP) Stock Options Chain | Quotes & News - Moomoo
CNS Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Clinical Milestones - dars.gov.et
CNS Pharmaceuticals Announces Strategic Oncology-Neurology Realignment - TipRanks
CNS Pharmaceuticals posts investor presentation; details $22.5M financing and strategic pivot - TradingView
Strategic pivot at CNS Pharmaceuticals (NASDAQ: CNSP) backed by $22.5M PIPE - Stock Titan
CNS Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Price to earnings forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Enterprise value to EBIT forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals (CNSP) Dips 4% as Shares Approach Key Support LevelTPO Profile - dars.gov.et
Enterprise value to EBITDA forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to sales forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
Price to book forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNS Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CNSP) - TradingView
BE50 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of CNS Pharmaceuticals, Inc. – NASDAQ:CNSP - TradingView
CNSP Forecast — Price Target — Prediction for 2027 - TradingView
CNS Pharmaceuticals (CNSP) Slides 4.7% as Biotech Sentiment Wavers; Support at $3.84 in FocusSwing Entry Signals - dars.gov.et
SK Biopharm taps Insilico in $2.5B AI CNS drug discovery deal - BioWorld News
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics - PR Newswire
Why did CNSP stock surge 330% today? - MSN
CNS Pharmaceuticals Inc (CNSP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNS Pharmaceuticals Inc (CNSP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CNS Pharmaceuticals Inc (CNSP) Institutional Confidence - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Stock Price, Quote, News & History - Benzinga
CNS Pharmaceuticals (CNSP) Surges 2.45% as Biotech Stock Tests Key ResistanceDark Pool Sentiment - dars.gov.et
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
What's going on with CNS Pharmaceuticals stock on Wednesday? - MSN
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnEarnings Cycle Outlook - newsline.com
CNSPCns Pharmaceuticals Inc Stock Price and Quote - Finviz
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
Cns Pharmaceuticals Inc (CNSP) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):